Recovery of HeLa cell population growth after treatment with 5,6‐dichloro‐1‐β‐D‐ribofuranosylbenzimidazole (DRB)

Dose‐response curves for the inhibition of heterogeneous nuclear RNA (hnRNA) synthesis in HeLa cells by 5,6‐dichloro‐1‐β‐D‐ribofuranosylbenzimidazole (DRB; 5–100 μM; 30 min) are biphasic and indicate the existence of two subpopulations of hnRNA molecules, one highly sensitive and the other completely resistant, as previously reported for molecules >1,000 nucleoides long (Tamm et al., 1976; Sehgal et al., 1976a). In the short‐term experiments, the drug‐sensitive synthesis of hnRNA was inhibited 50% at a DRB concentration of ∼7 μM, and 70% at 20 μM, whereas drug‐resistant synthesis, which comprises ∼20% of total, continued at DRB concentrations as high as 100 μM. After 24 hr of DRB treatment in medium containing 5% fetal calf serum, the increase in cell number in the exponentially growing population was inhibited by only 42% at 20 μM DRB, and the formation of colonies of ≥ ten cells was not decreased. DRB at 40 μM concentration decreased population growth by 76% and colony formation by 63%. Treatment with 60 μM DRB was sufficient to prevent a net increase in cell number and to reduce colony formation by 78%. After termination of treatment, the time required for the surviving population to begin rapid proliferation was directly related to the concentration of DRB used to treat cells and to the duration of treatment. After 24‐hr treatment with 40 μM DRB, cultures recovered within 1 day, whereas after 60 μM DRB, 3–4 days were required. After 40‐hr treatment with 60 μM DRB, 5–6 days were required for recovery, and after 80 μM DRB, 9–11 days. During the “dormant” period the cell number ranged from 15 to 60% of the initial number and was fairly stable for given conditions. After the “dormant” period, recovery was rapid. The population growth rate in cultures undergoing treatment with DRB is directly related to serum concentration; however, the recovery rate during the post‐treatment period is unaffeced by serum concentration.

[1]  I. Tamm HeLa cell RNA and protein syntheses. Effects of long-term treatment with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB). , 1984, Biochemical pharmacology.

[2]  I. Tamm,et al.  Inhibition of HeLa-S3 Cell Proliferation and Biosynthesis by 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) , 1983, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[3]  K. Weinhold,et al.  Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state. , 1982, Cancer research.

[4]  G. Molloy,et al.  Inhibition of messenger RNA synthesis by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole without its detectable accumulation in mouse T-lymphoma cells. , 1982, Archives of biochemistry and biophysics.

[5]  I. Tamm,et al.  Serum enhances the cycling and survival of HeLa cells treated with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[6]  V. Funanage Isolation and characterization of 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole-resistant mutants of the Chinese hamster ovary cell line , 1982, Molecular and cellular biology.

[7]  J. Darnell,et al.  Short capped hnRNA precursor chains in HeLa cells: continued synthesis in the presence of 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole. , 1980, Biochemistry.

[8]  L. Siminovitch,et al.  DRB resistance in Chinese hamster and human cells: Genetic and biochemical characteristics of the selection system , 1980, Somatic cell genetics.

[9]  I. Tamm,et al.  Early termination of heterogeneous nuclear RNA transcripts in mammalian cells: accentuation by 5,6-dichloro 1-beta-D-ribofuranosylbenzimidazole. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Sehgal,et al.  Superinduction of human fibroblast interferon production: further evidence for increased stability of interferon mRNA. , 1978, Virology.

[11]  J. Fried,et al.  Duration of the dormant state in an established cell line of human hematopoietic cells. , 1977, Cancer research.

[12]  P. Sehgal,et al.  A comparative study of the effects of certain halogenated benzimidazole ribosides on RNA synthesis, cell proliferation, and interferon production , 1977, The Journal of experimental medicine.

[13]  J. Darnell,et al.  The inhibition of DRB (5,6-dichloro-1-β-d-ribofuranosylbenzimidazole) of hnRNA and mRNA production in HeLa cells , 1976, Cell.

[14]  L. Caliguiri,et al.  Action of dichlorobenzimidazole riboside on RNA synthesis in L-929 and HeLa cells , 1976, The Journal of cell biology.

[15]  P. Sehgal,et al.  Regulation of human interferon production. II. Inhibition of interferon messenger RNA synthesis by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole. , 1976, Virology.

[16]  P. Sehgal,et al.  Human interferon production: superinduction by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole , 1975, Science.

[17]  D. Granick Nucleolar necklaces in chick embryo fibroblast cells. I. Formation of necklaces by dichlororibobenzimidazole and other adenosine analogues that decrease RNA synthesis and degrade preribosomes , 1975, The Journal of cell biology.

[18]  R. Bablanian,et al.  STUDIES ON THE MECHANISM OF POLIOVIRUS-INDUCED CELL DAMAGE. I. THE RELATION BETWEEN POLIOVIRUS,-INDUCED METABOLIC AND MORPHOLOGICAL ALTERATIONS IN CULTURED CELLS. , 1965, Virology.

[19]  I. Tamm,et al.  Glycosides of chlorobenzimidazoles as inhibitors of poliovirus multiplication. , 1957, Virology.

[20]  K. Folkers,et al.  INHIBITION OF INFLUENZA VIRUS MULTIPLICATION BY N-GLYCOSIDES OF BENZIMIDAZOLES , 1954, The Journal of experimental medicine.

[21]  L. Pfeffer,et al.  Assay of the inhibitory activities of human interferons on the proliferation and locomotion of fibroblasts. , 1981, Methods in enzymology.

[22]  K. Weinhold,et al.  The tumor dormant state. , 1981, Advances in cancer research.

[23]  P. Sehgal,et al.  Benzimidazoles and their nucleosides. , 1980, Antibiotics and chemotherapy.

[24]  P. Sehgal,et al.  Halogenated benzimidazole ribosides, Novel inhibitors of RNA synthesis. , 1978, Biochemical pharmacology.